AMENDMENTS TO THE CLAIMS:

This listing will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1-26 (Canceled).

Claim 27 (Withdrawn). An *in vitro* diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of *P. falciparum*, under conditions allowing an *in vitro* immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and *in vitro* detection of the antigen-antibody complexes formed.

Claim 28 (Withdrawn). The molecule or polypeptide composition according to claim 27 wherein said molecule or polypeptide composition further comprises B epitopes of the proteins resulting from the infectious activity of *P. falciparum*.

Claim 29 (Withdrawn). A kit for the *in vitro* diagnosis of malaria according to claim 27, wherein said kit comprises:

- a) one or more molecule or polypeptide compositions, wherein said molecule or polypeptide compositions comprise one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of *P. falciparum*;
- b) the reagents for making up a suitable medium for carrying out the immunological reaction; and
- c) the reagents allowing the detection of the antigen-antibody complexes produced as a result of the immunological reaction.

Claim 30 (Withdrawn). The kit according to claim 29, wherein said reagents in step c) bear a label or are recognized by a labelled reagent.

Claim 31 (Currently Amended). A <u>purified</u> polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 32 (Previously Presented). The polypeptide according to claim 31, wherein said T epitope has an amino acid sequence selected from the group of the amino acid sequence of SEQ ID NOS: 39-46.

Claim 33 (Withdrawn). The polypeptide according to claim 31, wherein said T epitope consists of the amino acid sequence of SEQ ID NO. 19.

Claim 34 (Withdrawn). The polypeptide according to claim 33, wherein said T epitope is preceded by one or more of the amino acid sequences of SEQ ID NOS. 2 to 18, wherein X₁ is Ser or Arg; X₂ is Glu or Asp; X₃ is Arg or Leu and X₄ is Glu or Gly.

Claim 35 (Previously Presented). The polypeptide of claim 31, further comprising at least one B epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 36 (Previously Presented). A vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in the hepatic cells.

Claim 37 (Previously Presented). The vaccine composition directed against malaria according to claim 36, wherein said T epitope is selected from the group of an amino acid sequence of SEQ ID NOS: 39-42, an amino acid sequence of SEQ ID NOS: 43-46 and amino acid sequence of SEQ ID NO. 19.

Claim 38 (Withdrawn). The vaccine composition directed against malaria according to claim 37, wherein said T epitope is preceded by one or more of the amino acid sequences of SEQ ID NOS. 2 to 18, wherein X_1 is Ser or Arg; X_2 is Glu or Asp; X_3 is Arg or Leu and X_4 is Glu or Gly.

Claim 39 (New). A synthetic polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*.